ReviewFrontiers in psychiatry2022
Histamine and histamine receptors: Roles in major depressive disorder.
Review in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Both donor and recipient sex determine behavioral and neuroimmune outcomes in a gut microbiota transfer experiment from the unpredictable chronic mild stress model of depression.Brain, behavior, & immunity - health · 2026Article
- Assessing the association between combined oral contraceptive use, selected biomarkers, and depressive episodes among premenopausal women: a protocol for a systematic review and meta-analysis.Systematic reviews · 2026Article
- SLC22A3 deficiency leads to cognitive impairment through the cardio-neuroinflammatory axis mediated HA/H1R/NLRP3 pathway in heart failure mice.Redox biology · 2026Article
- Preclinical Evidence for Antidepressant-like Effects of Histamine H3 Receptor Modulation: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Decoding GPCR signaling in living cells to advance early therapeutic discovery for neurological disorders.Frontiers in molecular neuroscience · 2026Review
- Effect of Venlafaxine on Inflammatory Level in Patients with Depression.Neuropsychiatric disease and treatment · 2026Article
- The dual functions of Ziziphi spinosae semen as medicine and food: origins, cross-domain applications, antidepressant metabolites, and pharmacological mechanisms.Frontiers in pharmacology · 2026Review
- Targeting Oligodendrocyte Dysfunction in Alzheimer's Disease: a New Frontier for Drug Repurposing with Antihistamines and Serotonin Receptor Agonists.Journal of molecular neuroscience : MN · 2025Review
- Investigating seasonal metabolic variations in bipolar disorder: a targeted metabolomics study.BMC psychiatry · 2025Article
- Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Plateau Environment, Gut Microbiota, and Depression: A Possible Concealed Connection?Current issues in molecular biology · 2025Review
- Drug-Induced Cognitive Impairment.Drug safety · 2025Review
- Integrating Machine Learning and Pharmacophore Features for Enhanced Prediction of H1 Receptor Blockers.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Transcriptomic decoding of brain function and cerebral blood flow impairments in first-episode drug-naive patients with major depressive disorder.Frontiers in psychiatry · 2025Article
- A Review on Lipid-based Nanoformulations for Targeting Brain through Non-invasive Nasal Route.Pharmaceutical nanotechnology · 2025Review
- Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/HMolecules (Basel, Switzerland) · 2024Article
- Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders.International journal of molecular sciences · 2024Review
- Molecular basis underlying changes of brain entropy and functional connectivity in major depressive disorders after electroconvulsive therapy.CNS neuroscience & therapeutics · 2024Article
- Jujuboside A Regulates Calcium Homeostasis and Structural Plasticity to Alleviate Depression-Like Behavior via Shh Signaling in Immature Neurons.Drug design, development and therapy · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the incidence of major depressive disorder (MDD) is high and its social impact is great, we still know very little about the pathophysiology of depression. The monoamine hypothesis of depression suggests that 5-HT, NE, and DA synergistically affect mood, which is the basis of current drug therapy for depression. However, histamine as a monoamine transmitter is rarely studied. Our review is the first time to illustrate the effect of histaminergic system on depression in order to find the way for the development of new antidepressant drugs. The brain neurotransmitter histamine is involved in MDD, and the brain histaminergic system operates through four receptors. Histamine and its receptors can also regulate the immune response to improve symptoms of depression. In addition, H3R can interact with other depression-related transmitters (including 5-HT, DA, GLU, and MCH); thus, histamine may participate in the occurrence of depression through other neural circuits. Notably, in rodent studies, several H3R and H1R antagonists were found to be safe and effective in alleviating depression-like behavior. To highlight the complex functions of histamine in depression, and reveals that histamine receptors can be used as new targets for antidepressant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.